from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2vPVk8f on August 9, 2017 at 07:49PM
Denmark-based pharmaceutical company Novo Nordisk says price drops may be on the horizon for its insulin products.
French pharmaceutical company Sanofi recently responded to competition from Eli Lilly and Boehringer by slashing the price of Lantus.
“We are well on track to deliver on our targets for 2017 based on sales growth driven by our new, innovative products within diabetes and obesity care and a continued focus on cost control,” Novo Nordisk President and CEO Lars Fruergaard Jørgensen said in a press release. “Although the formulary negotiations in the USA reflect the tough competetive envorinment, we remain confident that our long-term finmancial growth targets are achievable.”